Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NTJ3
UPID:
SMC4_HUMAN
Alternative names:
Chromosome-associated polypeptide C; XCAP-C homolog
Alternative UPACC:
Q9NTJ3; A6NLT9; D3DNL8; O95752; Q8NDL4; Q9UNT9
Background:
Structural maintenance of chromosomes protein 4, known as a central component of the condensin complex, plays a pivotal role in chromatin condensation during mitosis. This protein, also referred to as Chromosome-associated polypeptide C or XCAP-C homolog, is essential for converting interphase chromatin into mitotic-like condensed chromosomes. It works by introducing positive supercoils into relaxed DNA with type I topoisomerases and converting nicked DNA into positive knotted forms with type II topoisomerases.
Therapeutic significance:
Understanding the role of Structural maintenance of chromosomes protein 4 could open doors to potential therapeutic strategies.